发明授权
- 专利标题： MGLUR1 ANATGONISTS AS THERAPEUTIC AGENTS
- 专利标题（中）： MGluR1拮抗剂治疗物质
-
申请号： EP06848624.0申请日： 2006-12-11
-
公开(公告)号： EP1966220B1公开(公告)日： 2011-01-26
- 发明人: MATASI, Julius, J. , TULSHIAN, Deen , BURNETT, Duane, A. , WU, Wen-Lian , KORAKAS, Peter , SILVERMAN, Lisa, S. , THAVALAKULAMGARA, Sasikumar, K. , QIANG, Li , DOMALSKI, Martin, S.
- 申请人： Schering Corporation
- 申请人地址： 2000 Galloping Hill Road Kenilworth, NJ 07033-0530 US
- 专利权人： Schering Corporation
- 当前专利权人： Schering Corporation
- 当前专利权人地址： 2000 Galloping Hill Road Kenilworth, NJ 07033-0530 US
- 代理机构： Hussain, Deeba
- 优先权： US301672 20051213
- 国际公布： WO2007070393 20070621
- 主分类号： C07D495/14
- IPC分类号： C07D495/14
摘要：
In its many embodiments, the present invention provides tricyclic compounds of formula (I) (wherein J1 - J4, X, and R1- R5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.
公开/授权文献
- EP1966220A2 MGLUR1 ANATGONISTS AS THERAPEUTIC AGENTS 公开/授权日：2008-09-10
信息查询
